1. Awakening the “guardian of genome”: reactivation of mutant p53

   • Akshay Binayke
   • Sarthak Mishra
   • Harish Chander

   Review Article 15 October 2018 Pages: 1 - 15

   

2. Autophagy and its potent modulators from phytochemicals in cancer treatment

   • Chao-Yue Sun
   • Qian-Yu Zhang
   • Bing Feng

   Review Article 23 October 2018 Pages: 17 - 26

   

3. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters

   • Laure Deyme
   • Dominique Barbolosi
   • Florence Gattacceca

   Review Article 16 November 2018 Pages: 27 - 42

   

4. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET

   • Susumu Hijioka
   • Keiichiro Sakuma
   • Yasushi Yatabe

   Original Article 11 October 2018 Pages: 43 - 52

   

5. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy

   • Jacob Nersting
   • Stine Nygaard Nielsen
   • the Nordic Society of Paediatric Haematology and Oncology (NOPHO)

   Original Article 15 October 2018 Pages: 53 - 60

   

6. Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients

   • Brittney R. Starling
   • Parag Kumar
   • William C. Zamboni

   Original Article 16 October 2018 Pages: 61 - 70

   

7. Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis

   • Yu Bai
   • Hai-wei Wu
   • Yan-hua Zhang

   Original Article 24 October 2018 Pages: 71 - 79

   

8. Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats

   • Priyanka Arora
   • Courtney Huff Adams
   • Pankaj B. Desai

   Original Article 24 October 2018 Pages: 81 - 89

   

9. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers

   • Nathalie Rioux
   • Amy Kim
   • Joanne Schindler

   Original Article 27 October 2018 Pages: 91 - 96

   

10. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

    • Kristina Lindemann
    • Philip J. Beale
    • For ANZGOG and HCRN Collaborative Groups

    Original Article 27 October 2018 Pages: 97 - 105

    

11. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms

    • Akimitsu Maeda
    • Kei Irie
    • Shoji Fukushima

    Original Article 27 October 2018 Pages: 107 - 113

    

12. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

    • Osman Köstek
    • Muhammet Bekir Hacıoğlu
    • Bülent Erdoğan

    Original Article 29 October 2018 Pages: 115 - 122

    

13. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer

    • Hironori Fujii
    • Yunami Yamada
    • Akio Suzuki

    Original Article Open access 30 October 2018 Pages: 123 - 129

    

14. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

    • Ece Esin
    • B. Oksuzoglu
    • Turkish Oncology Group

    Original Article 30 October 2018 Pages: 131 - 143

    

15. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial

    • Koji Murono
    • Hiroshi Nagata
    • Soichiro Ishihara

    Original Article 01 November 2018 Pages: 145 - 150

    

16. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)

    • Nathalie Rioux
    • Sherri Smith
    • Peter G. Smith

    Original Article 01 November 2018 Pages: 151 - 160

    

17. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer

    • Yasushi Sato
    • Tamotsu Sagawa
    • Tetsuji Takayama

    Original Article 07 November 2018 Pages: 161 - 167

18. Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics

    • I. Kümler
    • P. Grundtvig Sørensen
    • D. L. Nielsen

    Original Article Open access 08 November 2018 Pages: 169 - 178

    

19. Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms

    • Sai-Qi Wang
    • Kai-Rui Zhou
    • Xiao-Bing Chen

    Original Article 08 November 2018 Pages: 179 - 189

    

20. Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

    • Robin L. Jones
    • Gary Mo
    • William D. Tap

    Original Article Open access 08 November 2018 Pages: 191 - 199

    

21. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study

    • Kazuo Sato
    • Yasuharu Toyoshima
    • Emiko Ohki

    Original Article Open access 09 November 2018 Pages: 201 - 207

    

22. Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients

    • W. Venus So
    • Tai-Hsien Ou Yang
    • Jianguo Zhi

    Short Communication Open access 03 December 2018 Pages: 209 - 213

    

23. Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

    • Soumaya Labidi
    • Nesrine Mejri
    • Hamouda Boussen

    Correction 10 December 2018 Pages: 215 - 215